VERAXA Biotech (NASDAQ: VRXA), a company focused on designing novel cancer therapies, has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has moved beyond the discovery phase and into the next stage of development. This milestone follows the successful completion of the discovery phase of its collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). The company will now engineer the final bispecific ADC candidate using the antibody binders identified through the collaboration, leveraging its proprietary antibody engineering, linker, and conjugation technologies.
Although VXA-222 is not based on VERAXA's BiTAC platform, it represents one of the company's more advanced development programs. The advancement of VXA-222 underscores VERAXA's commitment to building a diversified oncology pipeline that includes bispecific ADCs, T-cell engagers, and engineered antibody formats aimed at difficult-to-treat cancers.
In parallel, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, securing a strong foundation for its next-generation antibody technologies.
The expansion of VERAXA's patent portfolio is a strategic move to protect its innovative approaches in the competitive field of cancer therapeutics. By securing intellectual property around its BiTAC platform and other technologies, VERAXA aims to establish a strong position in the market and potentially create barriers for competitors.
This development is significant for VERAXA as it progresses its pipeline and fortifies its proprietary technologies. The advancement of VXA-222 is a key step toward bringing new treatment options to patients with difficult-to-treat cancers. The company's focus on next-generation antibody technologies positions it as an emerging leader in the biotech space.
Investors and industry observers will be watching closely as VERAXA continues to advance its programs and expand its IP portfolio. The company's ability to move VXA-222 forward and strengthen its patent estate could have important implications for its future growth and competitive standing.
